NIH-funded research U01 cooperative agreement

PRELUDE: Understanding how early life experiences shape child brain development

Official title: 1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium

Funded at Arkansas Children's Hospital Res Inst · NIH-11518959 · Data updated 2026-11-12

This nationwide study follows mothers and babies from before birth to age 10 to learn how experiences in pregnancy and early childhood affect brain development and behavior.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionArkansas Children's Hospital Res Inst
NIH-funded
Lab location1 site (Little Rock, United States)
Project startSeptember 30, 2021
Project endJune 30, 2027
Funding year2026
Award (this year)$2,066,540
NIH project number4U01DA055352-06
Project IDNIH-11518959 on NIH RePORTER

Who could benefit from this research

Could help

Expectant mothers and their children from birth to age 10 who are willing to participate in long-term imaging, assessments, and biospecimen collection across multiple sites.

Less likely to help

Families who are unable to commit to long-term participation or who prefer not to undergo imaging or biospecimen collection may receive no direct benefit.

What this research studies

We will recruit a large, diverse group of mothers and infants across 27 sites to collect brain imaging, brainwave data, and a wide range of behavioral and physiological measures. The study uses standardized protocols to map developmental trajectories over the first 10 years of life and to link environmental factors with outcomes. Researchers will share a rich dataset with the broader scientific community to help identify risk and protective factors that could inform interventions for children’s healthy development.

Why it matters

Potential benefit: If successful, findings could improve early identification of at-risk children and guide interventions to support healthier neurodevelopment.

How similar studies have gone: Previous neurodevelopmental studies have shown that early environmental factors influence later outcomes, and this study expands on those findings with a larger, harmonized dataset.

Where this research is happening

  • Arkansas Children's Hospital Res Inst
    Little Rock, United States
    Active

Researchers

  • Principal investigator: Ou, Xiawei — Arkansas Children's Hospital Res Inst
  • Study coordinator: Ou, Xiawei

Related research

Other NIH-funded projects on the same topics.

  • Shorter antifungal treatment for kids with candidemia

    A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.

    NIH research Arkansas Children's Hospital Res Inst · Little Rock, United States · NIH-11606539

  • Short Course vs Standard Course Antifungal Therapy for Pediatric Candidemia

    This study tests whether a shorter 7-day total antifungal treatment after an initial 7 days of echinocandin therapy is as effective as the usual 14-day course for children with candidemia.

    NIH research Arkansas Children's Hospital Res Inst · Little Rock, United States · NIH-11606535

  • Shorter antifungal treatment for kids with candidemia

    A multi-center study tests whether kids with candidemia can finish treatment earlier after an initial week of antifungal therapy than the standard two weeks total.

    NIH research Arkansas Children's Hospital Res Inst · Little Rock, United States · NIH-11606531

  • Shorter antifungal treatment for kids with candidemia

    This study tests whether children with candidemia can finish treatment after 7 days of an echinocandin if they are improving, instead of completing a full 14 days.

    NIH research Arkansas Children's Hospital Res Inst · Little Rock, United States · NIH-11606505

  • Shorter antifungal course for kids with candidemia

    A multi-center study tests whether 7 extra days of antifungal therapy after an initial week of treatment can be shortened safely for children with candidemia.

    NIH research Arkansas Children's Hospital Res Inst · Little Rock, United States · NIH-11606502

  • Shortened antifungal treatment for kids with candidemia

    A pediatric multicenter trial will test whether stopping antifungal therapy after 7 more days, following an initial 7 days of treatment, isas safe as continuing for 14 days.

    NIH research Arkansas Children's Hospital Res Inst · Little Rock, United States · NIH-11606491

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.